Evidence for Direct Involvement of the Capsid Protein in HIV Infection of Nondividing Cells

Masahiro Yamashita1, Omar Perez2, Thomas J. Hope3, Michael Emerman1*

1 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 2 Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, Illinois, United States of America, 3 Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America

HIV and other lentiviruses can productively infect nondividing cells, whereas most other retroviruses, such as murine leukemia virus, require cell division for efficient infection. However, the determinants for this phenotype have been controversial. Here, we show that HIV-1 capsid (CA) is involved in facilitating HIV infection of nondividing cells because amino acid changes on CA severely disrupt the cell-cycle independence of HIV. One mutant in the N-terminal domain of CA in particular has lost the cell-cycle independence in all cells tested, including primary macrophages. The defect in this mutant appears to be at a stage past nuclear entry. We also find that the loss of cell-cycle independence can be cell-type specific, which suggests that a cellular factor affects the ability of HIV to infect nondividing cells. Our data suggest that CA is directly involved at some step in the viral life cycle that is important for infection of nondividing cells.

Introduction

One of the properties that set HIV-1 and other lentiviruses apart from most of the other retroviruses is the ability to infect cells independent of the cell cycle [1,2]. This ability allows HIV-1 to propagate in nondividing cells in vivo such as resting CD4+ T cells [3] and terminally differentiated macrophages [4]. On the other hand, other retroviruses, such as murine leukemia virus (MLV), require cell-cycle progression to achieve productive infection [5,6].

There has been considerable controversy over the determinants of HIV infectivity in nondividing cells, with most studies concentrating on presumed determinants for nuclear import [2,7]. However, we recently showed that none of the previously identified karyophilic elements in the HIV genome are necessary for HIV to infect nondividing cells [8]. Rather, we demonstrated that the retroviral capsid (CA) protein is a major determinant for retrovirus infection in nondividing cells because an HIV-based chimera virus with MLV CA does not infect nondividing cells [8]. Nonetheless, it was not clear whether or not HIV CA was required to infect nondividing cells, or whether we had transferred a negative regulator of nuclear entry from MLV onto HIV. The present study was designed to determine whether HIV CA plays a direct role in the ability of this virus to infect nondividing cells.

The CA protein is a major structural protein that constitutes viral cores, and also plays a role in the early stages of infection (reviewed in [9]). Soon after virus entry into the target cell, incoming virions disassemble their cores in the cytoplasm (uncoating). However, it is not well understood exactly how the uncoating process takes place in acutely infected cells and which cellular factors may be involved [10,11]. Moreover, the uncoating steps may be different between HIV and MLV since most of the CA proteins of HIV dissociate from nucleoprotein complexes of incoming virions [10–17], whereas a large amount of CA remains bound to intracellular complexes of MLV after infection [18–20]. Therefore, one plausible hypothesis is that the difference in the uncoating process may influence the fate of retrovirus infection in nondividing cells by affecting further downstream events (nuclear import and integration) [21].

Here, we show that mutations in HIV CA can specifically reduce the infectivity of HIV in nondividing cells, and recapitulate the need for cell-cycle progression as seen for MLV. Furthermore, cell-cycle independence of most of the mutants is lost only in a particular cell type, which suggests that a cellular factor limits their replication in nondividing cells. We show that reverse transcription and nuclear import of these mutants proceed normally in nondividing cells. Finally, we show that, contrary to expectations, the kinetics of uncoating of the bulk of CA from the incoming virus cores does not correlate with the ability to infect nondividing cells. However, a functional assay for CA association with the reverse transcriptase complex (RTC) suggests that prolonged association of some CA with the RTC is associated with a loss of cell-cycle independence. These results suggest a direct role...

* To whom correspondence should be addressed. E-mail: memerman@fhcrc.org
Author Summary

HIV and related viruses are unusual among retroviruses in their ability to replicate independently of cell-cycle progression of target cells. However, the determinants of this phenotype have been controversial. Here, we identified mutations on the surface of the capsid (CA) protein that reduce the ability of HIV to infect nondividing cells. These mutations also confer cell-cycle dependency on HIV, even in dividing cells. Interestingly, some CA mutants lose cell-cycle independence only in certain cell types. Thus, these findings suggest that a cellular factor targeting CA regulates HIV-1 infection in nondividing cells. Surprisingly, these mutations do not appear to affect nuclear localization of viral genomes, which points to a novel regulation of the cell-cycle independence of HIV by the CA protein.

Results

Mutations in CA That Decrease the Ability of HIV-1 to Infect Nondividing Cells

A panel of HIV CA mutations was created and tested for their ability to infect nondividing cells (Table 1). These mutations were introduced in amino acids exposed on the surface of CA that had been previously characterized as mutations that did not have severe effects on virus assembly or budding, but decreased viral infectivity [22]. We introduced each mutation onto an HIV-1 provirus with a deletion in envelope (i.e., a single-round vector) that encodes either luciferase or green fluorescent protein (GFP) in place of the nef gene [21]. In our initial screen for infection of nondividing cells, we arrested HeLa cells in S-phase by addition of aphidicolin to the culture. As expected, the titer of MLV, which requires cell-cycle progression for productive infection, was reduced by 50-fold in nondividing cells relative to dividing cells, while infectivity of wild-type (WT) HIV-1 is equivalent in both dividing and nondividing cells (Figure 1A; Table 1). In contrast, CA mutants (T54A/N57A and Q63A/Q67A) were reduced in nondividing cells compared to dividing cells by 5- to 10-fold (Figure 1A; Table 1). The reduced infectivity of these CA mutants in nondividing cells is independent of multiplicity of infection, as the reduction in infectivity can be observed over a 3-log range of viral input (Figure 1A).

The decreased infectivity of the CA mutants in nondividing cells is more severe than previously characterized mutations in the vpr gene and the central purine tract [8], which had little effect on the ability of HIV to infect nondividing cells (Table 1). Importantly, the reduction of virus infectivity by itself does not necessarily cause the defect in the cell-cycle independence for infection, because some CA mutants that exhibit reduced overall infectivity still maintain the same property to infect nondividing cells as efficiently as dividing cells (for example, the P38A and K70A mutations; Figure 1A). In total, five separate mutants (E45A, T54A/N57A, Q63A/Q67A, L136D, and Q219A) were identified that exhibit at least a 4-fold decrease in the ability to infect nondividing cells (Table 1).

We also infected monocyte-derived macrophages (MDMs), a nondividing cell type that is a natural target of HIV infection. Viruses were first normalized for infectivity by titrating them on MT4 cells and equivalent MT4 cell infectious doses were used to infect macrophages. Figure 1B shows representative flow cytometry data showing that one of the mutants, T54A/N57A, is indeed very defective in nondividing macrophages. Namely, while infectivity of WT HIV-1 in MDMs (17%) was basically similar to that in MT4 cells (23%), the infectivity of T54A/N57A in MDMs (1.2%) was much lower than in MT4 cells (44%), as shown in Figure 1B.

Interestingly, the Q63A/Q67A mutant is affected only slightly in nondividing MDMs (Figure 1B). Thus, we also tested the ability of CA mutants to infect another cell line, HOS cells, that were dividing or nondividing. We found that the T54A/N57A mutant could not infect nondividing HOS cells, although it could infect dividing HOS cells (Figure 1C). However, the Q63A/Q67A mutant (Figure 1C) and all of the other CA mutants other than T54A/N57A (not shown) could infect nondividing HOS cells just as well as it could infect dividing HOS cells. These results indicate that there is cell-type specificity to the ability of most of the mutants to infect nondividing cells. Therefore, these findings suggest the presence of cellular factors that differentially regulate virus infectivity in non-cycling cells, but point to T54A/N57A as a region of CA that is important for infection of nondividing cells in diverse cell types.

Passage through Mitosis Alleviates Replication Block of HIV CA Mutants

MLV can only infect cells that pass through mitosis [5,6]. We asked if the HIV CA mutants that failed to infect nondividing cells had a requirement for mitosis similar to MLV. To determine if there is a cell-cycle stage necessary for productive transduction, we adapted a previously described method that does not involve an artificial block of the cell cycle [23]. Actively cycling cells were infected with retroviruses carrying

---

### Table 1. HIV Mutants Tested for Their Ability to Infect Nondividing Cells

| Virus              | Location in CA Structure | Infectivity in Nondividing Cells Relative to Dividing Cells (%)a |
|--------------------|--------------------------|---------------------------------------------------------------|
| HIV WT             | NA                       | 84.4 ± 22.9                                                   |
| HIVAcPPT           | NA                       | 98.8 ± 28.8                                                   |
| HIVAVpr            | NA                       | 58.1 ± 12.8                                                   |
| MLV                | NA                       | 3.39 ± 1.07                                                   |
| P38A               | Helix 2                  | 103 ± 6.00                                                    |
| E45A               | Helix 2                  | 17.7 ± 7.9                                                    |
| T54A/N57A          | Helix 3                  | 9.58 ± 2.08                                                   |
| Q63A/Q67A          | Helix 4                  | 16.8 ± 5.27                                                   |
| K70A               | Helix 4                  | 134 ± 36.8                                                    |
| E71A               | Helix 4                  | 70.1 ± 10.6                                                   |
| E128A/R132A        | Helix 7                  | 163 ± 21.9                                                    |
| L136D              | Helix 7                  | 23.7 ± 9.45                                                   |
| R143A              | Helix 7                  | 911 ± 30.5                                                    |
| Q219A              | Helix 11                 | 24.9 ± 5.40                                                   |

aDividing and nondividing cells were infected with virus stocks that transduce 5% to 25% of the cells to GFP-positivity by 2 d after infection. Infectivity in nondividing cells is shown as a percentage of infectivity in dividing cells. The data used here is the average of three independent infection experiments with standard deviations among those three experiments.

NA, not applicable.
doi:10.1371/journal.ppat.0030156.t001
the GFP gene, harvested at different time points after infection, and stained for DNA content with propidium iodide. Cell-cycle analysis of GFP-positive cells (i.e., cells that were successfully transduced with each GFP reporter virus) early after infection revealed that the cell-cycle status of GFP-positive cells in the MLV-infected cell population changes dramatically at different time points after infection, while the cell-cycle status of GFP-positive cells in the HIV-infected cell population remains relatively stable over time (Figure 2). This is likely due to the fact that MLV-transduced cells appear to be synchronized in the cell cycle, because the only transduced cells will be those that have passed through mitosis within a narrow time window after infection. On the other hand, HIV can transduce cells at any stage of the cell cycle, so HIV-transduced cells always appear asynchronous in the cell cycle. Specifically, most of the GFP-positive cells in the MLV-infected cell population were in S-phase 15 h after infection. These GFP-positive cells in MLV-infected cells were in late S-phase 17.5 h after infection, by 20 h they were in G2/M phase, and they completed mitosis from 20 to 22 h post infection (indicated by arrow, Figure 2A, middle). In contrast, GFP-positive cells in the HIV-infected cell population remain asynchronous in their cell-cycle profile at all time points post infection (Figure 2A, left).

We tested two CA mutants, T54A/N57A and Q63A/Q67A, in this assay, and found that cells infected with the HIV-1 CA mutant Q63A/Q67A are nearly indistinguishable from MLV in that they also are in S-phase at 15 h after infection and pass from G2/M to G1 between 20 and 22 h after infection (Figure 2A, right; the transition from G2/M to G1 is indicated by an arrow). We also obtained similar data using another CA mutant (T54A/N57A, Figure 2B). Therefore, these two CA mutants must have cell-cycle requirements for transduction similar to MLV and different from WT HIV. These results suggest that HIV CA mutants that fail to infect nondividing cells, can, like MLV, productively infect cycling cells only after they have passed through mitosis.

Replication of CA Mutants Was Blocked after Reverse Transcription in Interphase Cells

We concentrated our mechanistic studies on the T54A/N57A mutant because it had the strongest defect in nondividing cells (Table 1), and because it was affected in all cell types tested (Figure 1). There are ample precedents for mutations in CA that affect reverse transcription [24–30]. Thus, we were interested in knowing whether this mutant had a defect before or after reverse transcription. We therefore used a real-time PCR assay to compare late products of reverse transcription [31] for this mutant compared to those of WT HIV in dividing and nondividing cells. Remarkably, even though the amount of transduction (measured by GFP expression) is reduced to 5% to 10% of the levels of dividing

Figure 1. HIV CA Mutants Require Cell Division for Efficient Infection
(A) Dose-independent restriction of several CA mutants in nondividing cells. Nondividing cells were prepared by treatment of HeLa cells with aphidicolin and then infected with increasing amount of GFP-encoding viruses. Virus infectivity was measured by quantifying GFP-positive cells 2 d after infection. WT HIV-1 and MLV were used as controls. Open circles indicate infections with cycling cells and closed circles indicate infections with nondividing cells.

(B) Infection of MDMs with HIV-1. The WT strains together with CA mutants T54A/N57A and Q63A/Q67A were used to infect a human T cell line (MT4: upper panels) or MDMs (lower panels). Ten times more virus was used in MDMs, which are not as permissive as MT4 cells to HIV-1 infection. Expression of GFP, which is encoded by the reporter virus constructs, was examined 2 or 3 d after infection. The % of GFP-positive cells is indicated in the upper half of each flow cytometry panel. The data are representative of three independent experiments using at least three different donor PBMCs.

(C) Viral infectivity of CA mutants in HOS cells. Cell-cycle requirement for virus infection was examined by infectivity in dividing and nondividing HOS cells with WT or CA mutants encoding the GFP gene. Nondividing cells were prepared by treatment of aphidicolin (2 μg per ml) and the chemical was added throughout the experiment. Open circles indicate infections with cycling cells and closed circles indicate infections with nondividing cells. Shown here are the data that represent at least two independent experiments.

doi:10.1371/journal.ppat.0030156.g001
cells (Figure 3A), we found that the T54A/N57A mutant does not have a defect in synthesizing reverse transcription products in nondividing cells. Although we saw a slight decrease in the amount of the late reverse transcription products by T54A/N57A in nondividing cells, the same degree of reduction was also observed for WT HIV. Thus, we conclude that the replication defect of this CA mutant in nondividing cells occurs after reverse transcription.

Another hypothesis to explain why this CA mutant fails to infect nondividing cells is that viral DNA of these mutants is blocked from entering the nucleus before mitosis. Therefore, we investigated nuclear entry by measuring the copy number of 2-LTR circles, a marker of nuclear entry of viral genomes (Figure 3A), and by cell fractionation (Figure 3B). We found very little change in the formation of 2-LTR circles by T54A/N57A in nondividing cells. Although we saw a slight drop of 2-LTR in nondividing cells compared with dividing cells (2.5-fold), this amount of decrease is not likely to explain the reduced infectivity in nondividing cells (19-fold decrease from the infectivity in dividing cells). We obtained substantially similar data for another CA mutant (E45A).

Nuclear entry of viral DNA was also examined by subcellular fractionation followed by real-time PCR for quantification of reverse transcription products. Our cell fractionation protocol was verified by showing that cytoplasmic protein, LDH-1, contaminated the nuclear fraction to less than 4% (Figure 3B, top right), and a nuclear protein, lamin B, could not be detected in the cytoplasmic fraction (Figure 3B, bottom right). Using this assay we found that 70% of the viral DNA of the CA mutant T54A/N57A was associated with the nuclear fraction (Figure 3B). More importantly, the amount of viral DNA associated with the nuclear fraction is similar between WT and T54A/N57A (Figure 3B). Finally, we looked at the localization of the 2-LTR circles in these fractions, and found that in both WT and the T54A/N57A mutant, the 2-LTR circles were more abundant in the nuclear fraction than in the cytoplasmic fractions in aphidicolin-treated cells (Figure 3C). These results suggest this CA mutant has the ability to access the nucleus in nondividing cells, and the block to this mutant in nondividing cells may be at a stage post–nuclear entry.

Uncoating of CA Mutants

We previously hypothesized that uncoating of the viral core might be the rate-limiting step for the ability of a retrovirus to infect non-cycling cells [2]. Thus, we sought to examine the uncoating of these CA mutants in vivo. We used a recently developed assay [32] for in situ determination of the CA association with intracellular viral complexes. Briefly, virus is labeled with GFP-Vpr [33] and the membrane is labeled by
was examined by dividing the copy number of viral DNA in nuclear fractions by that in both fractions (cytoplasmic plus nuclear fractions). The data shown here is a representative of two independent experiments; although the ratio of viral DNA associated with nuclear fractions differed between two experiments, the amount of viral DNA associated with nuclear fraction remains the same between WT and the CA mutant. Controls with reverse transcriptase inhibitors showed that contamination by plasmid DNA accounted for less than 1% of the values (not shown). Western blotting analysis was performed to ensure the integrity of subcellular fractionation (right panels). Contamination was checked by checking a cytoplasmic protein, LDH-I (upper lanes) and a nuclear protein, lamin B (lower lanes). To, total cell lysates; Cy, cytoplasmic extract; Nu, nuclear lysates. Twenty micrograms of proteins were loaded on the gel except for the following dilutions. Cytoplasmic extract was diluted by 5-fold; 5-, 25-, and 125-fold dilutions correspond to lanes 4, 3, and 2 (upper lanes).

(C) Subcellular localization of 2-LTR circles. Copy numbers of 2-LTR circles in cytoplasmic (white boxes) and nuclear (black boxes) fractions were measured by real-time PCR. The same fractions as in the (B) were used in this PCR assay.

doi:10.1371/journal.ppat.0030156.g003
order to more closely match the normal entry patterns of virus.

A human T cell line, Jurkat cells, was infected with either WT HIV-1 or T54A/N57A, both of which are based on replication-competent viruses expressing luciferase. CsA was added at different times after inoculation of virus to see how long the effects of CsA on HIV-1 infection last. When the drug was added simultaneously with the initiation of infection of the viruses, WT HIV was moderately affected by the treatment of CsA (~5-fold), whereas T54A/N57A was more severely restricted (~25-fold) by the presence of the drug (Figure 5A).

The kinetics of the sensitivity of the two viruses to CsA appeared distinct. For WT virus, the sensitivity to CsA inhibition rapidly declined within the first few hours after infection (Figure 5A), and the half-maximal effect of CsA was seen at about 2 h. This result is in good agreement with the uncoating as for WT in Figure 4. The effects of CsA on the infection with T54A/N57A were more complex (Figure 5A). There was an increased inhibition of virus infectivity when CsA was added at 1 h after infection relative to when it was added at the same time as the infection (Figure 5A). This result was repeatable (N = 3). However, after that initial inhibition by CsA, there was a much slower gradual loss of CsA sensitivity, and the half-maximal effect was not observed until after 8 h.

As controls for the function of the RTC, we also measured the kinetics of resistance to a reverse-transcriptase inhibitor, nevirapine, and found that both WT and the T54A/N57A mutant had an equivalent kinetic sensitivity with a 50% maximal inhibition approximately 4 h after infection (Figure 5B). These results demonstrate that the T54A/N57A does not affect the extent (Figure 3), or kinetics (Figure 4), of reverse transcription. Nonetheless, the kinetics of CsA sensitivity of this mutant suggest that functional association of CA with infections particles in T cells might occur with complex kinetics that could have a major effect on downstream events that are important for the ability to infect cells in a cell-cycle independent fashion.

Discussion

Our previous study indicated that a chimeric HIV-1 having MLV CA fails to infect nondividing cells [21]. This suggests either that MLV CA negatively regulates virus infectivity in nondividing cells or that HIV CA is an essential factor for HIV infection of nondividing cells. Here, we provide direct evidence that HIV-1 CA is an essential factor since we identify mutations in CA that affect this process.

We previously proposed that inefficient disassembly of the viral core is responsible for the poor infectivity of MLV in nondividing cells [9] since there appears to be a difference in the amount of CA-associated MLV RTC and/or pre-integration complex (RTC/PIC) compared to that of HIV [14,19]. Thus, we expected mutants of HIV CA that failed to infect nondividing cells also to uncoat CA from the RTC less slowly than WT HIV. However, this does not seem to be the case (Figure 4). One of the mutants, Q63A/Q67A, behaved this way (Figure 4), but another mutant, T54A/N57A, appears to uncoat more rapidly than WT HIV (Figure 4). Thus, there appears to be no correlation between the uncoating of the bulk of CA soon after infection and the ability to infect cells independent of the cell cycle. It is also possible that CA mutations indirectly affect the rate of reverse transcription, which in turn could affect the composition of the PIC. However, we found no difference in either the amount of reverse transcription products made by the CA mutants studied here (Figure 3), or more importantly, no difference in the kinetics of completion of reverse transcription (Figure 5B).

However, all assays that look at total events soon after infection have the caveat that it is not possible to distinguish events leading to productive infection from events that are dead-end products. Thus, we also adapted an assay previously used to characterize CA association with RTC/PIC that relied on the kinetic sensitivity of HIV to the Trim-CypA restriction in owl monkey cells [34]. In this assay, only infectious events are scored, because the final read-out requires transcription from the provirus. We wished to use this assay in human T cells, and therefore relied on the kinetic sensitivity to cyclophilin enhancement (i.e., decreased infectivity in the presence of CsA) rather than the restriction to Trim-CypA. We found that there is a functional association of CA with the RTC/PIC for several hours after infection (Figure 5) in Jurkat T cells. In addition, one of the CA mutants (T54A/N57A) was sensitive to CsA for a longer period of time than WT virus (on the order of 8–10 h), suggesting that T54A/N57A may retain some CA on the RTC for a longer period of time than WT (Figure 5). In contrast, the in situ uncoating assay found that this mutant uncoated faster than WT virus (Figure 4). Thus, an alternative interpretation is that the in situ assays detect the presence of an intact conical core structure, while the CsA sensitivity of HIV infection detects another function that...
is associated with a subset of CA that stays associated with the RTC for extended periods after uncoating. This could explain the increased sensitivity of the T54A/N57A mutant to CsA (Figure 5).

Another CA mutant (Q63A/Q67A) that lost the cell-cycle independence for infection was found to contain more CA proteins in the mature RTC in both the in situ uncoating assay (Figure 4), and in an independent biochemical assay [35]. These results support a model whereby some degree of association of CA with the RTC/PIC prevents infection of nondividing cells, and that total uncoating is the rate-limiting step for efficient infection of nondividing cells. Nonetheless, other models for a role of CA in other early steps of the virus life cycle that is important for cell-cycle independence cannot be ruled out.

The mechanistic basis of uncoating is not well understood, but the CA protein is the likely candidate for regulation of core disassembly due to differential levels of its association with intracellular virus complexes. Thus, it is possible that substitution of certain amino acid residues in the CA may alter the stability of virus cores and thus the kinetics of CA disassembly from the viral core in infected cells. However the cell-type specificity for the replication block of HIV CA mutants in nondividing cells argues against this possibility; if the intrinsic property of a virus by itself determines the reduced infectivity, then we would not likely see any difference in viral infectivity between different cell types. Instead, these data suggest the involvement of cellular factors in regulating the role of incoming viral cores in target cells.

Both MLV and HIV CA mutants require progression of cell cycle through mitosis for efficient replication (Figure 2). The long-held idea to explain the requirement of mitosis for productive infection by MLV is that MLV lacks the ability to transport its viral DNA into the nucleus across intact nuclear envelope of interphase cells and that mitosis literally removes this barrier of nuclear membrane because of nuclear membrane breakdown during mitosis [6]. Consistent with this idea, incorporation of tRNA has been implicated in the role of nuclear transport of HIV, and is absent in MLV [36]. However, we found that viral DNA of CA mutants is associated with the nucleus and results in the accumulation of 2-LTR circles. Thus, our data suggest that the HIV CA mutants only transduce cells that go through mitosis (Figure 2), but that nuclear import per se is not the limiting step. Indeed, others have also shown that HIV-1 CA can affect a post-nuclear entry step [35]. In addition, there is a report suggesting that factors other than the nuclear membrane govern the infectivity of MLV in nondividing cells (macrophages) [37]. Thus, while nuclear import of PICs is undoubtedly necessary during the viral life cycle, these data suggest that there are steps past nuclear entry that may be critical determinants for the ability to infect nondividing cells. The direct implication of CA in the infection of nondividing cells by HIV may help uncover novel means of disrupting this critical pathway in the viral life cycle.

**Materials and Methods**

**Cell culture.** Cell lines were grown in DMEM supplemented with either 10% calf serum or fetal bovine serum (FBS). MDMs were prepared as described before [21] and cultured in RPMI with 10% FBS and 5% human serum.

**Viral constructs.** The proviral DNA pLai is an infectious molecular clone of HIV-1 [38]. Reporter virus constructs created based on pLai and encoding either the luciferase gene or the EGFP gene in place of the nef open reading frame were described previously (pLaiEnv-luc2 and pLaiEnv-GFP3, respectively) [21]. They lack a functional envelope gene, allowing single-cycle replication assays by pseudotyping virions with envelope proteins supplied in trans. DNA fragment encompassing the HIV-1 CA-encoding region was digested from pLai with ApalI and BssHII and cloned into either pSL1180 or pBluescript II, both of which were also processed with the same combination of restriction enzymes. Point mutations were introduced in the plasmid DNA containing a part of HIV-1 sequence by using a commercial PCR mutagenesis kit. DNA constructs with a substitution were subject to DNA sequencing to ensure that any unwanted change is not made 

**PLoS Pathogens | www.plospathogens.org**

**Conflict of Interest:** None declared.
a Q63A/Q67A mutation in the CA sequence with the previously reported Vpr mutant [39].

**Virus stocks.** Virus stocks were prepared by transfection of 293T cells with various combinations of DNA constructs. Transfections were performed with a commercial liposome-based transfection reagent (TransIT-LT1; Mirus). An expression vector of VSV-G protein was used to make pseudotyped viruses [40]. HIV-1 proviral DNA constructs encoding either luciferase or GFP were co-transfected with pL-Δ8.91. Virus stocks for MLV were prepared by transfection of four DNA constructs: Gag-Pol vector, retroviral transfer vector, pL-VSV-G, and a construct for Tat expression (PCMV-tat: to allow efficient expression of VSV-G, which is under control of HIV-1 LTR promoter) [40]. Either pK3 [40] or pCS2+mgP21 was used as Gag-Pol expression plasmid construct. For GFP-encoding, MLV-based retroviral transfer vectors, either pLXCG or pLXS were used (for luciferase-encoding MLV-based retroviral transfer vectors, pLNCtuc was used [21]). Culture supernatant was harvested 2 and 3 d post transfection. The supernatant was cleared of cell debris by low-speed centrifugation and passed through 0.22-μm filters. Aliquots of the filtered supernatant were frozen at −80°C. Supernatant of the virus stocks that exhibit a low titer in infectivity assay was concentrated by ultracentrifugation after low-speed spin and filtration. Concentrated viruses were also kept at −80°C until use.

**Infectivity assays.** Infectivity of HIV CA mutants was compared between dividing and nondividing cells by single-cycle replication assay. HeLa or HOS cells were seeded at 8 × 10^5 per well for 12-well plates or at 4 × 10^5 per well for 24-well plates 1 d before infection. Nondividing cells were prepared by seeding three times more cells than the protocol for dividing cells and by treatment with 2 μg of aphidicolin per ml. The cells were infected with increasing amounts of virus stocks in the presence of 20 μg of DEAE-dextran per ml. Viral attachment was enhanced by spinoculation at 1,200g for 30 to 60 min at room temperature. Inoculated cultures were washed away and fresh medium were added to the plates. Two days after infection, infectivity was examined by enumerating GFP-positive cells with fluorescence-activated cell sorter for GFP-encoding viruses or by measuring the luciferase activity in lysed cells for lucifase-encoding viruses.

MDMs were infected with GFP-encoding virus stocks 9 to 10 d after preparation along with MT4, a human T cell line, in the presence of 20 μg of DEAE-dextran per ml. GFP-positive cells were scored for 30 min post infection. At the indicated time point post infection, HeLa cells on glass coverslips were fixed with 3.7% formaldehyde (Polysciences) in 0.1 M Pipes buffer (pH 6.8). Coverslips were stained with anti-p24 mAb AG50 (NIH AIDS Research and Reference Reagent Program) in blocking solution (10% normal donkey serum [Jackson ImmunoResearch Laboratories], 0.1% Triton X-100, 0.01% NaN3) for 30 min at RT for primary stain and secondarily stained with labeled Cy5 donkey anti-mouse antibodies (Jackson ImmunoResearch Laboratories). Coverslips were mounted on slides with Gel Mount (Biomedica). Images were collected and deconvolved with a DeltaVision microscope and software (Applied Precision). Following deconvolution, the number of GFP-positive virions was assessed at each time point and each virion was individually inspected for punctate mCherry fluorescent signal and p24 Cy-5 signal.

**Time-course experiments with CsA.** Jurkat cells were seeded in 96-well plates at 100,000 cells per well. Virus inocula that produce approximately 100,000 relative light units in luciferase assays were used to inoculate the cells. Infections were enhanced by addition of 20 μg of DEAE-dextran per ml and by a brief spinoculation. Viral-containing medium was washed away and fresh medium was added at the start of infection. CsA was resuspended in DMSO was added at various time points after infection. The infected cells were lysed in a cell culture lysis buffer (Promega) at 48 h after infection and luciferase activity of the lysates was measured using the Luciferase Assay System (Promega).

**Acknowledgments.** We thank the NIH AIDS Research and Reference Reagent Program for antibody to p24CA and nevirapine. We are grateful to Shari Kaiser, Tsai-Yu Lin, Molly OhAinle, and Yegor Voronin for critical reading of the manuscript and the FHCRF Flow Cytometry Lab for assistance. We also thank Lily Wu for assistance with the time-course experiment in Figure 5.

**Author contributions.** All authors conceived and designed the experiments, analyzed the data, and wrote the paper. MY, OP, and ME performed the experiments. MY and ME contributed reagents/materials/analysis tools.

**Funding.** This work was supported by NIH grant AI73085 to ME, a New Investigator award from the University of Washington Center for AIDS Research (AI27575) to MY, R01 AI47770 to TJH, and an ASM Robert D. Watkins Graduate Research Fellowship to OP.

**Competing interests.** The authors have declared that no competing interests exist.

**References**

1. Katz RA, Greger JG, Skalka AM (2005) Effects of cell cycle status on early events of HIV-1 infection. J. Virol. Cell Biol. 79: 88–98.
2. Ziegler D, Schuberth H, Zupancic M, Wietgrefe S, Staskus KA, et al. (1999) Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286: 1353–1357.
3. Weinberg JB, Matthews TJ, Collen BR, Malim MH (1991) Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med 174: 1477–1482.
4. Lewis PF, Emerman M (1994) Passage through mitosis is required for
HIV Capsid and Nondividing Cells

oncoretroviruses but not for the human immunodeficiency virus. J Virol 68: 510–516.
6. Roe T, Reynolds TC, Yu G, Brown PO (1993) Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12: 2099–2108.
7. Fassati A (2006) HIV infection of non-dividing cells: a divisive problem. Retrovirology 3: 74.
8. Yamashita M, Emerman M (2005) The cell cycle independence of HIV infections is not determined by known karyophilic viral elements. PLoS Pathog 1: e18. doi:10.1371/journal.ppat.0010018
9. Freed EO (1998) HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251: 1–15.
10. Anwarakul P, Wacharapornin P, Srichatrapimuk S, Chutpongthanes T, Panthavatana P (2005) Uncoating of HIV-1 requires cellular activation. Virology 337: 93–101.
11. Narayan S, Young JA (2004) Reconstitution of retroviral fusion and uncoating in a cell-free system. Proc Natl Acad Sci U S A 101: 7721–7726.
12. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, et al. (1993) Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A 90: 6125–6129.
13. Farnet CM, Haseltine WA (1991) Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 65: 1910–1915.
14. Fassati A, Goff SP (2001) Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 75: 3626–3635.
15. Karageorgos L, Li P, Burrell C (1995) Characterization of HIV replication complexes early after cell-to-cell infection. AIDS Res Hum Retroviruses 9: 817–823.
16. Khiytni DK, Dimmock NJ (2002) Characterization of a human immunodeficiency virus type 1 pre-integration complex in which the majority of the cDNA is resistant to DNase I digestion. J Gen Virol 75: 5389–5390.
17. Miller MD, Farnet CM, Bushman FD (1997) Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 71: 5892–5895.
18. Bowerman B, Brown PO, Bishop JM, Varmus HE (1989) A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev 3: 469–478.
19. Fassati A, Goff SP (1999) Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus. J Virol 73: 8919–8925.
20. Li L, Oliveira JY, Mitchell RS, Butler SL, et al. (2001) Role of the nontranslated DNA end joining pathway in the early steps of retroviral infection. EMBO J 20: 3272–3281.
21. Yamashita M, Emerman M (2004) Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol 78: 5670–5678.
22. von Schwedler U, Kornbluth RS, Trono D (1994) The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A 91: 6992–6996.
23. Slafer TK, Jacobberger JW (1998) Cell cycle analysis of retroviral vector gene expression during early infection. Cytometry 31: 235–241.
24. Alin K, Goff SP (1996) Amino acid substitutions in the CA protein of Moloney murine leukemia virus that block early events in infection. Virology 222: 359–351.
25. Cartier C, Sivard P, Tranchat C, Decimo D, Desgranges C, et al. (1999) Identification of three major phosphorylation sites within HIV-1 capsid. Role of phosphorylation during the early steps of infection. J Biol Chem 274: 19434–19440.
26. Fitzon T, Leschonsky B, Bierer B, Paulus C, Schroder J, et al. (2000) Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology 268: 294–307.
27. Forshey BM, von SU, Sundquist WI, Aiken C (2002) Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 76: 5667–5677.
28. Reicin AS, Paik S, Berkowitz RD, Luban J, Lowy I, et al. (1995) Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J Virol 69: 642–650.
29. Tang S, Murakami T, Agresta BF, Campbell S, Freed EO, et al. (2001) Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol 75: 9357–9366.
30. Leschonsky B, Ludwig C, Bierer B, Wagner R (2007) Capsid stability and repackaging of human immunodeficiency virus type 1 are influenced critically by charge and size of Gag residue 183. J Gen Virol 88: 207–216.
31. Butler SL, Hansen MS, Bushman FD (2001) A quantitative assay for HIV DNA integration in vivo. Nat Med 7: 631–634.
32. Campbell EM, Perez O, Melar M, Hope TJ (2007) Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology 360: 286–293.
33. McDonald D, Vodicka MA, Lucero G, Svinkina TM, Borisy GG, et al. (2002) Visualization of the intranuclear behavior of HIV in living cells. J Cell Biol 159: 441–452.
34. Perez-Caballerio D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD (2005) Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol 79: 15567–15572.
35. Dismuke DJ, Aiken C (2006) Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J Virol 80: 3712–3720.
36. Zaitseva L, Myers R, Fassati A (2006) tRNAs promote nuclear import of HIV-1 intracellular reverse transcription complexes. PLoS Biol 4: e352. doi:10.1371/journal.pbio.0040332
37. Jarrosson-Wuilleme L, Goujon C, Bernaud J, Rigal D, Darlix JL, et al. (2006) Human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 80: 1152–1159.
38. Peden K, Emerman M, Montagnier L (1991) Changes in growth properties of clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185: 661–672.
39. Taylor AR, Purohit S, Collins S, Robinson T, Hackett A, et al. (2005) Proline-rich nuclear localization sequence in human immunodeficiency virus type 1 gene product is required for viral replication in nondividing cells. Virology 360: 286–293.
40. Bartz SR, Vodicka MA (1997) Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods 12: 337–342.
41. Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 980–982, 984–986, 989–990.